Revenue: As of FY2025 Q3, the actual value is USD 1.941 K.

EPS: As of FY2025 Q3, the actual value is USD -0.04.

EBIT: As of FY2025 Q3, the actual value is USD 334.56 K.

Segment Revenue

• Net Revenue: For the three and nine months ended September 30, 2025, net revenue was $1,941, with no revenue reported for the same periods in 2024.

Operational Metrics

• Gross Profit: For the three and nine months ended September 30, 2025, gross profit was $884, with no gross profit reported for the same periods in 2024.
• Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $1,146,381, compared to $215,256 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $17,502,751, compared to $543,149 for the same period in 2024.
• Net Loss: For the three months ended September 30, 2025, net loss was - $1,850,493, compared to - $216,269 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $19,773,114, compared to - $544,162 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $3,995,648, compared to - $744,755 for the same period in 2024.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $5,940,286, compared to $750,122 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: Aspire Biopharma Holdings, Inc. plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company intends to submit a section 505(b)(2) NDA for its high-dose aspirin product following positive clinical trial results, with plans to seek FDA 505(b)(2) Fast Track designation in the first quarter of 2026.
• Non-Core Business: Aspire is exploring licensing possibilities for its sublingual melatonin sleep-aid product and has developed formulations for sublingually administered vitamins and semaglutide. The company is also developing caffeine products and considering formulations for other drug classes.